US Patent

US8946262 — Methods of preventing and treating gastrointestinal dysfunction

Method of Use · Assigned to Adolor Corp · Expires 2030-02-12 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of preventing and treating gastrointestinal dysfunction, particularly postoperative and post-partum ileus, using 4-aryl-piperidine derivatives.

USPTO Abstract

Methods of preventing and treating gastrointestinal dysfunction, particularly postoperative ileus and post-partum ileus, in a patient undergoing surgery or other biological stress by administering 4-aryl-piperidine derivatives are disclosed.

Drugs covered by this patent

Entereg (ALVIMOPAN) · Cubist Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1655`	—	Entereg

Patent Metadata

Patent number: US8946262
Jurisdiction: US
Classification: Method of Use
Expires: 2030-02-12
Drug substance claim: No
Drug product claim: No
Assignee: Adolor Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.